CompletedPhase 3

A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Japan374 participantsStarted 2013-10-09

Plain-language summary

The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety and pharmacokinetics of KPS-0373 in SCD patients.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Japanese SCD patients with mild to moderate ataxia Exclusion Criteria: * Patients with secondary ataxia * Patients with clinically significant hepatic, renal, or cardiovascular dysfunction

What they're measuring

SARA (Scale for the Assessment and Rating of Ataxia)

Timeframe: 24 weeks

Trial details

NCT IDNCT01970098

SponsorKissei Pharmaceutical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-01

View on ClinicalTrials.gov More Spinocerebellar Degeneration trials